BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Add as a preferred source on Google
-- Company presentation scheduled for March 13, 2018 --
SOUTH SAN FRANCISCO, Calif., March 06, 2018 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present at the Cowen and Company 38th Annual Health Care Conference in Boston. Achaogen management will present at 8:00 a.m. Eastern Time on Tuesday, March 13th, 2018.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived on the website for 30 days following the conference.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination for the treatment of serious bacterial infections due to ESBL-producing Enterobacteriaceae. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
[email protected]
Media Contact:
Denise T. Powell
Red House Consulting, LLC
[email protected]
